China Resources Sanjiu Medical & Pharmaceutical stock
000999.SZSHZChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd., HealthcareISIN CNE0000011K8
73Score 73 out of 100, Strong
Price and trend
58 / 100
Price history
−17% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 3.6% below it.
Since February 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 55).
The price is 18% below its 52-week high. Largest decline in 20 years: 51% (May 2010 to January 2012).
Chart figures for advanced users
- SMA 50$3.72
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.90
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)55
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.32
- The lowest closing price of the last twelve months.
- Resistance$4.58
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. belongs to the Drug Manufacturers (Specialty & Generic) industry (China) and, with a market value of $6.25B, is number 38 of 77 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.74B (up 14.4% year on year) and earnings of $513.15M (up 1.6%).
- For fiscal 2026, analysts expect on average revenue of $4.78B (up 0.9%) and adjusted earnings per share of $0.30 (down 11.5%).
Show more
- MEQIRI Score 73 out of 100 (Strong): rank 91 of 702 in Healthcare, median 53.
- The P/E is 12.9 (Drug Manufacturers (Specialty & Generic) median 32.5, own median of recent years 16.9).
- Our model puts fair value at $6.36, with the price 41% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Modestly valuedP/E 12.9, Drug Manufacturers (Specialty & Generic) median 32.5, own median 16.9.Valuation 83
- Growing faster than its industryRevenue up 18.3% a year since 2020, Drug Manufacturers (Specialty & Generic) median 10.2%.Growth 83
- Below fair valuePrice 41% below the fair value of $6.36.Valuation 83
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are stability and fundamentals, while momentum holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $4.54 and expensive above $10.60 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $3.26 (cash-flow model) and $9.46 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $6.09, at 6.3% it would be $6.77.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 3.9% on the twelve months before. Revenue has grown strongly since 2006, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 54%, operating 15%, net 11%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 22 Mar 2027in 129 days
- Last reported
- 23 Oct 2026EPS reported $0.04 (expected $0.04)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 3.0% since 28 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.30−3.6%
- Revenue
- $4.78B−2.9%
- Earnings per share
- $0.33−3.0%
- Revenue
- $5.09B−3.3%
MEQIRI has stored the estimates since 28 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at China Resources Sanjiu Medical & Pharmaceutical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 73
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Amneal PharmaceuticalsAMRX $7.56B58
- Huadong Medicine000963.SZ $6.9B60
- Alkem LaboratoriesALKEM.NS $6.74B65
- Lantheus HoldingsLNTH $6.62B76
- Apotex HealthAPTX.TO $6.17B68
- Gland PharmaGLAND.NS $5.8B70
- Sumitomo Pharma4506.T $5.54B57
- Ipca LaboratoriesIPCALAB.NS $5.12B69
ETFs that hold China Resources Sanjiu Medical & Pharmaceutical
Held by 39 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| HSBC MSCI China A UCITS ETF USDH41K | 0.14% | 0.30% | €68.31M |
| WisdomTree Emerging Markets SmallCap Dividend UCITS ETFWTED | 0.10% | 0.54% | €35.5M |
| Xtrackers Harvest CSI300 UCITS ETF 1DRQFI | 0.08% | 0.65% | €251.68M |
Show 5 more
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.08% | 0.65% | €10.81M |
| iShares Edge MSCI EM Value Factor UCITS ETF5MVL | 0.04% | 0.40% | €1.51B |
| Amundi MSCI EM Asia ESG Broad Transition UCITS ETF AccLCUA | 0.03% | 0.25% | €661.06M |
| Franklin EM Multi-Factor Equity UCITS ETFFLXE | 0.02% | 0.30% | €102.64M |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.02% | 0.60% | €31.52M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.